Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224871 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2398945 | 0.79 | ALDH1A1 (0.42) | CYP1A2RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL2398947 | 0.79 | ALDH1A1 (0.42) | CYP1A2RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL1225646 | 0.73 | LMNA (0.45) | PTGS1PTGS2ALOX5GRM4HCAR2 | |
| SCHEMBL2400810 | 0.73 | SMN1; SMN2 (0.45) | GRM4HCAR2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2400811 | 0.73 | SMN1; SMN2 (0.45) | GRM4HCAR2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1225648 | 0.73 | LMNA (0.45) | PTGS1PTGS2ALOX5GRM4HCAR2 | |
| SCHEMBL1801877 | 0.69 | HCAR2 (0.60) | PTGS1PTGS2CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL29022469 | 0.69 | HCAR2 (0.48) | PTGS1PTGS2CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12018827 | 0.69 | HCAR2 (0.60) | PTGS1PTGS2CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-22 | — | — | US | claimed |
| US-8193177-B2 | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases | ANGION BIOMEDICA CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-22 | — | — | US | disclosed |
| US-7879898-B1 | treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema | ANGION BIOMEDICA CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. | 2010-10-07 | — | — | US | disclosed |
| EP-1355921-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | North Shore-Long Island Jewish Health System (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002002593-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | HGF, HGFAC, HDGF | PTGS1 2601/4885PTGS2 3307/4885CYP1A1 4722/4885 |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | HGF, HDGF, HGFAC | PTGS1 1046/4885PTGS2 1483/4885CYP1A1 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.